Expert Insights On Patient Recruitment

  1. How The ACA Subsidy Lapse Could Hurt Clinical Trial Enrollment 3/12/2026

    The relationship between the Affordable Care Act (ACA) enhanced premium subsidies and clinical research isn’t widely understood, so consultant Devra Densmore is clearing things up, including how coverage loss could impact trial enrollment.

  2. When A Clinical Trial Surfaces In An AI Chat, What Happens Next? 3/2/2026

    AI is soon becoming the first interpreter of your clinical trial. Understand its implications for enrollment design, screening efficiency, and ultimately program predictability.

  3. The Problem With Excluding Children From GLP-1 Trials In The U.S. 2/19/2026

    In the U.S., roughly 15 million children are obese. But many are excluded from GLP-1 research. Obesity expert Evan Nadler, MD, explains why that's problematic.

  4. How AI-Enabled Personal Health Tools Are Reshaping Clinical Trial Workflows 2/17/2026

    Learn how AI-enabled personal health technologies are impacting key aspects of trial operations while also exploring operational challenges that clinical operations leaders must manage in this AI-driven era.

  5. 4 Steps For Representative Enrollment In Rare Disease Trials 2/16/2026

    Discover the D.A.T.A. method and its utility in enrolling diverse representative patient populations in rare disease clinical trials.

  6. FDA Issues Final Guidance On Clinical Trial Participation: What You Need To Do Now 2/13/2026

    On December 15, 2025, the FDA finalized its guidance Enhancing Participation in Clinical Trials, formally updating expectations for enrollment and trial design. Here's what you can do now.

  7. What ChatGPT Ads Will Really Mean For Clinical Trials 2/10/2026

    AI health assistants may be used to surface clinical trials earlier in patient journeys, and advertising inside conversational AI is best understood as the next logical step in that same progression.

  8. Building Patient Trust In Research Through Connection Driven-Transparency 2/4/2026

    The question is not whether trust matters but how industry, sponsors, and investigators can bridge the trust gap to drive patient participation.

  9. Patient Trust In Pharma Is Low; Here's How To Rebuild It 2/2/2026

    CISCRP's Annick de Bruin and Shalome Sine provide strategies for building patient trust based on the findings from their Perceptions & Insights Study.

  10. The U.S. Trial Advantage Is Eroding 1/30/2026

    Once the go-to location for trials, the U.S. is now seeing competition from APAC, driven by political, economic, and workforce pressures domestically and rapid growth abroad.